Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions.

[1]  G. Roubin,et al.  17-β estradiol inhibits neointima formation after coronary angioplasty in swine , 1996 .

[2]  N L Geller,et al.  Asymptomatic Cardiac Ischemia Pilot (ACIP) Study. Improvement of cardiac ischemia at 1 year after PTCA and CABG. , 1995, Circulation.

[3]  C von Birgelen,et al.  Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. , 1995, The American journal of cardiology.

[4]  V. Miller,et al.  901–40 Gender-related Differences in Smooth Muscle Cell Proliferation in Response to Estradiol and Dihydrotestosterone , 1995 .

[5]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[6]  W. O’Neill,et al.  Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. , 1994, The New England journal of medicine.

[7]  A. Quyyumi,et al.  Acute Vascular Effects of Estrogen in Postmenopausal Women , 1994, Circulation.

[8]  A. Quyyumi,et al.  Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. , 1994, Circulation.

[9]  G. Gibbons,et al.  The emerging concept of vascular remodeling. , 1994, The New England journal of medicine.

[10]  P. Ramwell,et al.  Estradiol inhibition of arterial neointimal hyperplasia after balloon injury. , 1994, Journal of vascular surgery.

[11]  S. Reis,et al.  Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. , 1994, Circulation.

[12]  J. Tijssen,et al.  Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group. , 1993, Circulation.

[13]  R. Califf,et al.  A Comparison of Directional Atherectomy with Coronary Angioplasty in Patients with Coronary Artery Disease , 1993 .

[14]  Charles L. Brown,et al.  Can restenosis after coronary angioplasty be predicted from clinical variables? , 1993, Journal of the American College of Cardiology.

[15]  D. Herrington,et al.  Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. , 1992, Journal of the American College of Cardiology.

[16]  M. Hong,et al.  Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. , 1992, The American journal of cardiology.

[17]  G A Colditz,et al.  Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. , 2004, Preventive medicine.

[18]  J. Manson,et al.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991, The New England journal of medicine.

[19]  M. Savage,et al.  Restenosis after coronary angioplasty: A multilvariate statistical model to relate lesion and procedure variables to restenosis☆ , 1991 .

[20]  F. Kazim,et al.  Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty. , 1991, Journal of the American College of Cardiology.

[21]  G. Colditz,et al.  Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆ , 1991 .

[22]  S. Goldberg,et al.  Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty--a report from the M-HEART Group. , 1990, The American journal of cardiology.

[23]  H. S. Klopfenstein,et al.  Estrogen modulates responses of atherosclerotic coronary arteries. , 1990, Circulation.

[24]  B. Lewis,et al.  Identifying patients at high risk for restenosis after percutaneous transluminal coronary angioplasty for unstable angina pectoris. , 1989, The American journal of cardiology.

[25]  S. Ellis,et al.  Importance of stenosis morphology in the estimation of restenosis risk after elective percutaneous transluminal coronary angioplasty. , 1989, The American journal of cardiology.

[26]  P. Serruys,et al.  Coronary angioplasty for unstable angina: immediate and late results in 200 consecutive patients with identification of risk factors for unfavorable early and late outcome. , 1988, Journal of the American College of Cardiology.

[27]  P W Serruys,et al.  Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. , 1988, Circulation.

[28]  M. Nobuyoshi,et al.  Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. , 1988, Journal of the American College of Cardiology.

[29]  M. LeFree,et al.  Automated quantitative coronary arteriography: morphologic and physiologic validation in vivo of a rapid digital angiographic method. , 1987, Circulation.

[30]  B Meier,et al.  Restenosis after successful coronary angioplasty in patients with single-vessel disease. , 1986, Circulation.